An interventional study of Vertebroplasty in Vertebral Fracture and Multiple Myeloma, sponsored by Spine Centre of Southern Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Spine Centre of Southern Denmark · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial. The trial will compare two groups of patients which either receive regular medical treatment of their vertebral lesion(s) or vertebroplasty in addition to regular medical treatment. Our goal is to investigate the effectiveness of vertebroplasty and determine the role of surgical treatment in the overall treatment of patients with multiple myeloma and vertebral lesion(s).
Patients identified by the attending consultant as eligible are invited to participate. Patients who express an interest in participating will be given written and oral information on the purpose, nature and implications of study-participation.
Possible candidates will be identified at the departments of Hematology where the patients are treated for their disease. All Danish departments of Hematology will be invited to participate.
The hematologist will inform the patient of the protocol and decide if they fulfil the inclusion and exclusion criteria. If the patient wishes to participate the hematologist will fill out screening forms regarding disease stage, lines of treatment, current disease status, bisphosphonate status, and pain relief treatment. The hematologist will refer the patient to their collaborating surgical department. The surgical department will decide if the patient has contraindications for surgery and inform the patient of the risk of the procedure.
If the patient decides to participate, he or she will fill out forms regarding ODI, VAS pain score, QoL.
Before randomization, the patients will be divided into two groups, stratifying between patients with known multiple myeloma with new diagnosed spine fracture and relevant pain ≤ 3 months prior to inclusion and patients with newly diagnosed multiple myeloma with new spine fracture.
Furthermore, to ensure balanced control and intervention groups the included patients at randomization will be stratified according to 1) panned PVP of 1 vs 2-4 levels, and 2) former vertebral fractures that are not planned treated with PVP.
The patients will be randomized to either PVP treatment or conservative treatment by drawing. It is therefore not possible for patients to choose between the treatments.
Patients randomized to vertebroplasty will be referred to a facility performing vertebroplasty. Patients randomized to non-vertebroplasty will receive the departments' usual care with the option to change treatment arm after 4 weeks.
The randomization will be performed by the diagnosing clinician, but orchestrated by one individual central to the clinics. The clinics will receive sealed envelopes containing the choice of randomization equally divided between PVP and conservative treatment. When all sealed envelopes have been used for randomization, the clinics will receive new envelopes.
It will not be possible to randomize more than one patient at a time. All patients will be contacted by a research nurse on a weekly basis the first 12 weeks after enrolment and after 3 and 12 months.
All patients randomized to vertebroplasty will undergo standard operative treatment involving a standard scheduled outpatient clinical control with the surgeon 12-weeks post-operative including long-standing radiographs of the spine.
144 studies on the registry are indexed under Spinal Fractures; 24 are open to participants now.
This study's planned enrollment of 90 is above the median of 80 across 85 interventional studies indexed under Spinal Fractures.
Browse Spinal Fractures studies →Spine Centre of Southern Denmark is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with vertebroplasty in addition to regular medical treatment.
Procedure: Vertebroplasty
Patients treated with regular medical treatment.
Injection of cement into vertebral lesion(s)
Improvement in back-specific disability
Oswestry Disability Index v2.1 (ODI): Each section is scored on a 0-5 scale, with 5 representing the highest disability.
Time frame: 4 weeks post-initiation of treatment
Improvement in back-specific disability
ODI
Time frame: Up to 12 months post-initiation of treatment
Back and leg pain
Visual Analogue Scale (VAS): 0-100 scale, with 100 representing the largest amount of pain
Time frame: Up to 12 months post-initiation of treatment
Movement, personal care, usual activities, pain/discomfort, depression/anxiety
Self-reported questionnaire on quality of life using: - European Quality of Life - 5 Dimension (EQ-5D): 0-2 scale, with 2 representing the highest disability EQ-5D contains questions on topics contributing to the overall feeling of quality of life: * movement * personal care * usual activities (ex. occupation, family activities) * pain/discomfort * depression/anxiety.
Time frame: Up to 12 months post-initiation of treatment
Long-term stability of treated vertebra(e)
X-rays will be used to analyze long-term stability.
Time frame: 12 months post-initiation of treatment
General health services
General questionnaires on wether or not and to what extend the patients have been using general health services.
Time frame: Up to 12 moths post-initiation of treatment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All data of long-term value will be stored, e.g. for use in future studies on shorter-term or long-term follow-up or reuse. Metadata and anonymized data will be available for other researchers if possible due to confidentiality and GDPR.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Started Mar 2021 (actual). Primary completion is estimated for Jul 2025, 52 months after the start.
Of 36 interventional studies with no phase under Spinal Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 70. This study's planned 52 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spine Centre of Southern Denmark